Medifast’s Optavia Cuts Visceral Fat by 14% While Preserving 98% Lean Mass
Medifast’s Optavia program delivered a 14% visceral fat reduction and preserved 98% lean mass over 16 weeks in randomized trials, supported by 18 RCTs and 40+ peer-reviewed publications. Structured meal replacements with coach support outperformed self-directed diets in fat mass loss and sustainable metabolic health outcomes.
1. Clinical Trial Results
Over 16 weeks, participants on the Optimal Weight 5 & 1 Plan achieved a 14% drop in visceral fat while retaining 98% of lean mass in randomized controlled trials. Coaching participants lost up to ten times more weight and 17 times more fat than self-guided dieters, underscoring the efficacy of human support.
2. Research Portfolio
The program’s clinical approach is validated by 18 randomized controlled trials, over 30 scientific analyses, 40+ peer-reviewed journal articles and more than 100 scientific presentations. This robust evidence base distinguishes Optavia’s structured meal replacement plans in a fragmented weight loss market.
3. Industry Impact
The global weight management market was valued at $16.3 billion in 2025, with increasing scrutiny on clinical validation. Structured, protein-focused replacement plans that prove visceral fat reduction and lean mass preservation are setting new standards for metabolic health outcomes.
4. Implications for Medifast
Enhanced clinical credibility may drive higher enrollment and recurring revenue for Medifast’s Optavia brand, potentially boosting market share and investor confidence. Investors will watch subscription growth and margin sustainability as key indicators of commercial leverage from these findings.